Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by stock_itchon Aug 16, 2015 8:15pm

67 Views

Post# 24023208

RE:RE:RE:RE:RE:RE:SunPharma failure on USA Absorica market share

Like I said previously it's very standard to have revenue thresholds that have to be maintained in order to maintain exclusivity. The fact that Ranbaxy has one of the patents complicates things. Also the fact that Sun Pharma has amagamated with Ranbaxy could work in CPH's favor, depending on opt out options in the case of ownership changes. I'm sure CPH's legal team is looking at all this to consider options now that CHP has it's own US sales force. Will get interesting.

Bullboard Posts

Silver Range Resources: A hidden gem in the mining industry